Renal cell carcinoma accounts for approximately 2.4% of all malignancies in adults, with more than 400,000 new cases diagnosed and about 180,000 deaths worldwide in 2020 according to GLOBOCAN data. It is the ninth most common malignant neoplasm in the United States and has been increasing in recent years. The age standardized rate is 4.6 for the world average overall, with 6.1 for men and 3.1 for women.
North America had the highest incidence at 12.2, followed by Australia and New Zealand at 10.2, and Europe at 9.5. Incidence rates in Asia and Africa were considerably lower. The high values in developed countries suggest that not only race but also lifestyle plays a role in incidence patterns.
Approximately 180,000 people died from RCC in 2020, accounting for 1.8% of all cancer patient deaths. Mortality was higher in Eastern Europe and Latin America. Increased detection of early RCC lesions through advanced imaging has improved survival rates, with 5-year survival for early detection reaching 93%, though metastatic disease still carries a poor prognosis at 12%.
Most renal cell carcinomas are derived from tubular tissue, with clear cell RCC being the most common subtype at 75% of cases, followed by papillary cell RCC and chromophobe RCC. Clear cell RCC has a worse prognosis than the other two types. The average age of diagnosis in the U.S. is 64 years, making it predominantly a disease of the elderly.
RCC is approximately 1.5 times more common in males than in females, which may be partly due to differences in lifestyle habits that contribute to carcinogenesis. Women have fewer papillary RCCs and more chromophobe RCCs, though the cause of this histological difference remains unknown.
Incidence varies by ethnic group in the United States, with a higher risk among Native Americans and African Americans, and lower risk among Asian Americans. Contributing factors include not only racial differences but also lifestyle factors such as diet and exercise, education, and access to medical care.
While most RCC is sporadic, several hereditary diseases with specific germline gene mutations are recognized risk factors. Von Hippel-Lindau disease, the most well-known hereditary condition associated with RCC, accounts for 5% of clear cell RCC cases and involves mutations on chromosome 3 that lead to increased expression of hypoxia-inducible factor, enhancing angiogenesis and tumor progression.
BAP1 tumor predisposition syndrome is an autosomal dominant condition associated with increased risk of malignant mesothelioma, melanoma, basal cell carcinoma, and RCC. Hereditary papillary RCC involves mutations in the MET oncogene on chromosome 7, while hereditary leiomyomatosis and RCC involves mutations in the fumarate hydratase gene with a 15% lifetime risk of developing type 2 papillary RCC.
Additional hereditary syndromes include SDH-deficient RCC, tuberous sclerosis complex involving mTOR pathway activation, Birt-Hogg-Dube syndrome caused by FLCN gene mutations, PTEN hamartoma syndrome with a 34% lifetime RCC risk, and hyperparathyroidism-jaw tumor syndrome involving CDC73 gene mutations. Each syndrome has distinct genetic mechanisms and management strategies.
Tobacco smoking has been linked to RCC through a mixture of carcinogens, with epidemiologic evidence showing a dose-response relationship between risk and amount smoked, and decreased risk with longer smoking cessation. Heavy smokers with 22.5 or more pack-years had more than 50% increased RCC risk compared to nonsmokers in the VITAL study.
Meta-analysis of more than 24 articles showed a pooled relative risk of 1.31 for all smokers, 1.36 for current smokers, and 1.16 for former smokers. A Japanese prospective study also found that heavy smokers had an increased hazard ratio of 1.50 for RCC, though the effect has not been well investigated in Asian populations.
Over-the-counter analgesics including acetaminophen and other NSAIDs have been associated with increased RCC risk. Trichloroethylene, an organic solvent used in semiconductor cleaning, is highly carcinogenic and is a predisposing risk factor for RCC along with liver cancer and lymphoma.
Moderate alcohol consumption has been reported to have a protective effect on RCC incidence, with European studies showing significantly reduced odds ratios for moderate drinkers compared to abstainers. High red meat intake was associated with increased cancer risk, while consumption of cruciferous vegetables has been reported to reduce RCC risk.
Obesity is significantly associated with RCC risk, with the VITAL study confirming a hazard ratio of 1.71 for individuals with BMI of 35 or greater. Each 5 kg of body weight increase raises RCC risk by 25% for men and 35% for women. Interestingly, a U-shaped association was observed in thin men, suggesting that both extremes of body weight may confer risk.
Coffee-containing compounds including cafestol and kahweol have shown anti-inflammatory, anti-angiogenesis, and anti-tumorigenic properties in experimental studies, suggesting potential anticancer effects. These dietary and lifestyle factors represent important targets for primary prevention of RCC.
Hypertension is independently associated with RCC risk, with a hazard ratio of 1.70 in the VITAL study. A meta-analysis of 18 prospective studies found that a history of hypertension was associated with 67% increased risk of RCC, and for every 10 mmHg increase in blood pressure, RCC risk increased by 10 to 22%. The biological mechanism is hypothesized to involve chronic renal hypoxia and lipid peroxidation.
Renin-angiotensin system inhibitors used for hypertension may have a chemopreventive effect on RCC, with hypertensive patients taking these medications showing smaller tumor size, fewer metastases, and significantly prolonged overall survival after surgical treatment.
Type 2 diabetes has been associated with an increased risk of several types of cancer, though its relationship to RCC remains unclear. In the Nurses' Health Study, type 2 diabetes was significantly associated with increased RCC risk in women, and high glucose levels among men were additionally associated with increased risk.
Screening programs can improve survival by detecting RCC in early, curable stages, but ideal screening modalities have not yet been established. Candidate biomarkers in blood and urine have been reported, including serum microRNAs, urinary proteins, metabolomics, proteomics, and amino acid profile analysis, though none have reached practical clinical application.
The most promising urine biomarkers are aquaporin 1 and perilipin 2, with sensitivity of 85-92% and specificity of 87-100% for early non-invasive detection of clear cell or papillary RCC subtypes. These biomarkers achieved area under the curve values of 0.95 and 0.91 respectively, and can distinguish RCC from healthy controls, benign renal tumors, and non-renal urological cancers.
A combined three-marker serum assay based on nicotinamide N-methyltransferase, L-plastin, and non-metastatic cell 1 protein demonstrated 95.7% sensitivity and 90% specificity with an AUC of 0.932 for distinguishing RCC from healthy controls, though it has limited ability to differentiate between RCC and benign renal tumors.
DNA methylation alterations occur early during cancer development in clear cell RCC. Cell-free methylated DNA immunoprecipitation and high throughput sequencing can sensitively detect early-stage tumors, with the top 300 differentially methylated regions achieving an AUC of 0.99 in plasma and 0.86 in urine for detecting all stages of RCC.
MicroRNAs show promise as diagnostic biomarkers with pooled sensitivity of 0.85 and specificity of 0.84 for RCC diagnosis, and an AUC of 0.91. A panel of five serum miRNAs can clearly distinguish RCC patients from non-cancer controls, demonstrating clinical diagnostic value for early-stage detection.
The most widely studied circulating miRNA for RCC is miR-210, which is expressed in response to hypoxia through HIF-1-alpha, a key player in renal carcinogenesis. Multiple urinary miRNAs including miR-210-3p, miR-122, miR-1271, miR-15b, and miR-15a have also shown diagnostic potential, with miR-15a differentiating RCC from benign tumors with 98.1% sensitivity and 100% specificity.
Long non-coding RNAs have shown remarkable potential as both diagnostic markers and therapeutic targets for RCC. A five-lncRNA serum panel can distinguish benign tumors from clear cell RCC with an AUC of 0.90. Serum levels of GIHCG and LINC00887 were significantly elevated in RCC patients, with AUCs of 0.920 and 0.803 respectively.
Metabolomics approaches using tissue and urine samples have identified pathways relevant to RCC diagnosis including glutathione, tryptophan, and glycolysis. A diagnostic prediction model using urinary metabolites achieved 93.1% sensitivity and 95.0% specificity with an AUC of 0.966. A large prospective study found 25 blood metabolites robustly associated with RCC risk, primarily glycerophospholipids.
Proteomics studies have identified fibronectin 1 and SPARC as promising plasma and urine biomarkers. Lipidomics identified 39 lipids that discriminate between tumor and healthy tissue, while amino acid profiling using eight serum amino acids achieved an AUC of 0.81 for RCC detection. These multi-omics strategies represent the future of non-invasive RCC screening.
The incidence and mortality of RCC vary widely around the world, with hereditary risk factors that cannot be modified but behavioral and environmental factors that can be improved. Prevention efforts targeting smoking, obesity, hypertension, diabetes, and occupational exposure are therefore critical for reducing the global burden of this disease.
Secondary prevention through early detection is equally important, with adequate follow-up for hereditary diseases and early detection of sporadic cases potentially reducing the number of deaths due to RCC. A significant number of biomarkers have been studied for diagnostic and prognostic purposes across multiple omics platforms.
Despite promising results from miRNAs, lncRNAs, metabolomics, proteomics, and amino acid profiling, none of these biomarkers are yet accurate enough to be widely used in clinical practice. Further research to identify, validate, and elucidate new markers for RCC remains a critical priority for improving patient outcomes.